SuperworthInhibikase Therapeutics market cap IKT
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $221.9M
- Highest close in our data
- $348.8M
- Sep 2026
Inhibikase Therapeutics is worth $221.9M at the close on Oct 23, 2026, at $1.59 a share.
That is up 93% over the last year and up 344% over five years.
Its highest close in our data was $348.8M in Sep 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $221.9M | $112.8M | $348.8M | +48% |
| 2025 | $150.4M | $106.3M | $223.1M | −27% |
| 2024 | $204.9M | $7.5M | $231.1M | +2514% |
| 2023 | $7.8M | $4.5M | $22.1M | −38% |
| 2022 | $12.6M | $12.4M | $42M | −66% |
| 2021 | $37M | $19.2M | $60.6M | n/a |
Against its peers
Companies in Biotechnology nearest Inhibikase Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| IKTInhibikase Therapeutics | $221.9M |
| PLXProtalix BioTherapeutics | $205.5M |
| MGTXMeiraGTx | $884.6M |
| VCELVericel | $2.2B |
| Peer median | $884.6M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Inhibikase Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.